IPSC vs. IVVD, NKTX, KNTE, FATE, BLUE, IMTX, MESO, HUMA, RLAY, and SRRK
Should you be buying Century Therapeutics stock or one of its competitors? The main competitors of Century Therapeutics include Invivyd (IVVD), Nkarta (NKTX), Kinnate Biopharma (KNTE), Fate Therapeutics (FATE), bluebird bio (BLUE), Immatics (IMTX), Mesoblast (MESO), Humacyte (HUMA), Relay Therapeutics (RLAY), and Scholar Rock (SRRK). These companies are all part of the "medical" sector.
Century Therapeutics (NASDAQ:IPSC) and Invivyd (NASDAQ:IVVD) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, profitability, analyst recommendations, community ranking, risk, dividends, earnings and valuation.
Century Therapeutics has higher revenue and earnings than Invivyd. Century Therapeutics is trading at a lower price-to-earnings ratio than Invivyd, indicating that it is currently the more affordable of the two stocks.
Century Therapeutics has a beta of 1.44, meaning that its share price is 44% more volatile than the S&P 500. Comparatively, Invivyd has a beta of 0.89, meaning that its share price is 11% less volatile than the S&P 500.
Century Therapeutics currently has a consensus target price of $13.20, indicating a potential upside of 344.44%. Invivyd has a consensus target price of $11.33, indicating a potential upside of 515.94%. Given Invivyd's stronger consensus rating and higher probable upside, analysts clearly believe Invivyd is more favorable than Century Therapeutics.
50.2% of Century Therapeutics shares are owned by institutional investors. Comparatively, 70.4% of Invivyd shares are owned by institutional investors. 6.8% of Century Therapeutics shares are owned by insiders. Comparatively, 17.9% of Invivyd shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Century Therapeutics received 20 more outperform votes than Invivyd when rated by MarketBeat users. However, 66.67% of users gave Invivyd an outperform vote while only 60.87% of users gave Century Therapeutics an outperform vote.
Invivyd has a net margin of 0.00% compared to Century Therapeutics' net margin of -9,742.41%. Century Therapeutics' return on equity of -59.74% beat Invivyd's return on equity.
In the previous week, Invivyd had 6 more articles in the media than Century Therapeutics. MarketBeat recorded 7 mentions for Invivyd and 1 mentions for Century Therapeutics. Century Therapeutics' average media sentiment score of 1.87 beat Invivyd's score of 0.24 indicating that Century Therapeutics is being referred to more favorably in the media.
Summary
Invivyd beats Century Therapeutics on 9 of the 17 factors compared between the two stocks.
Get Century Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for IPSC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IPSC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Century Therapeutics Competitors List
Related Companies and Tools
